Low expression of CD200 predicts shorter time-to-treatment in chronic lymphocytic leukemia

Yi Miao(Jiangsu Academy of Agricultural Sciences), Jianyong Li(Jiangsu Province Hospital)
Oncotarget
January 19, 2016
10.18632/oncotarget.6948
Cited by 24

Related Papers

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study
|Blood|2012|390
miR-17-92 cluster microRNAs confers tumorigenicity in multiple myeloma
|Cancer Letters|2011|119
HLA-Mismatched Microtransplant in Older Patients Newly Diagnosed With Acute Myeloid Leukemia
|JAMA Oncology|2017|48
The distinct clinical features and prognosis of the CD10+MUM1+ and CD10−Bcl6−MUM1− diffuse large B-cell lymphoma
|Scientific Reports|2016|42